Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Polypoidal Choroidal Vasculopathy

  • Home
  • Polypoidal Choroidal Vasculopathy
Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD
Posted innews Ophthalmology

Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD

Posted by MedXY By MedXY 05/27/2026
This study found that younger age, better baseline vision, smaller hemorrhage size, and thicker subfoveal choroid predicted better 1-year visual outcomes after fovea-involving submacular hemorrhage from nAMD or PCV.
Read More
High-Dose Aflibercept 8 mg Demonstrates Sustained Visual Gains and Durability in Polypoidal Choroidal Vasculopathy
Posted innews Ophthalmology

High-Dose Aflibercept 8 mg Demonstrates Sustained Visual Gains and Durability in Polypoidal Choroidal Vasculopathy

Posted by MedXY By MedXY 12/24/2025
This post hoc analysis of the PULSAR trial reveals that aflibercept 8 mg provides noninferior visual outcomes and comparable anatomic regression to standard 2 mg dosing in PCV patients, while allowing for significantly extended treatment intervals and reduced injection burden.
Read More
  • Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data
  • Unveiling the Phenotype of Unclassified Pulmonary Hypertension: A Hidden Spectrum of Early Heart Failure with Preserved Ejection Fraction
  • Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial
  • Decoding SLC4A3 Mutations in Short QT Syndrome: Insights from hiPSC-Derived Cardiomyocytes into Ventricular Arrhythmia and Sudden Cardiac Death
  • Decade-Long Outcomes of SAPIEN 3 TAVR vs. Surgery in Intermediate-Risk Aortic Stenosis Patients
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in